CN103432150A - Compound medicine of synergistic tartaric acid tylosin soluble powder - Google Patents
Compound medicine of synergistic tartaric acid tylosin soluble powder Download PDFInfo
- Publication number
- CN103432150A CN103432150A CN201310364033XA CN201310364033A CN103432150A CN 103432150 A CN103432150 A CN 103432150A CN 201310364033X A CN201310364033X A CN 201310364033XA CN 201310364033 A CN201310364033 A CN 201310364033A CN 103432150 A CN103432150 A CN 103432150A
- Authority
- CN
- China
- Prior art keywords
- tylosin
- tartaric acid
- trimethoprim
- tylosin tartrate
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention relates to a compound medicine of synergistic tartaric acid tylosin soluble powder, and aims to provide a compound synergistic tartaric acid tylosin for injection of livestock, which can be used for achieving a rapid and definite curative effect on breathing system infection and complications of livestock. The medicine comprises the following components by weight: 1 part of tartaric acid tylosin, 1 part of kanamycin sulfate, 0.2 part of trimethoprim, 0.2 part of cosolvent and 0.05-0.1 part of pain alleviator, wherein the cosolvent is citric acid or succinic acid or a combination of the citric acid and the succinic acid; the pain alleviator is procaine hydrochloride or lidocaine hydrochloride or a combination of the procaine hydrochloride and the lidocaine hydrochloride. The compound synergistic tartaric acid tylosin for injection of livestock contains medicine components of three types, namely tartaric acid tylosin, kanamycin sulfate and trimethoprim, can solve the problems that tartaric acid tylosin is narrow in antimicrobial spectrum and cannot well control secondary infection during the treatment of mycoplasma infection, as well as trimethoprim is difficult to dissolve in water, realizes a synergy effect on tartaric acid tylosin and kanamycin sulfate, and is accurate in dosage and convenient to use.
Description
The application is that application number is: 201210277167.3, and patent name is: the dividing an application of the patent of invention of " injection use compound potentiation tylosin tartrate for animals ", the original bill applying date: on 08 06th, 2012.
Technical field
The present invention relates to injection use compound potentiation tylosin tartrate for animals, or claim the compound medicine of potentiation tylosin tartrate soluble powder.
Background technology
From the state of development of current China animal husbandry, current poultry respiratory system infection is occurred frequently, complication is seriously large to poultry harm.On market, also there is no now the medicine of comparatively desirable treating both the principal and secondary aspects of a disease.By investigation domestic, international market is found, market is in the urgent need to a kind of efficacy stability, good effect, stability, complication serious specific medicine occurred frequently to the poultry respiratory system infection high, easy to use.
In prior art, tylosin tartrate belongs to vinegar class animal specific antibacterials in macro ring, mainly most gram-positive bacterias, Gram-negative coccus, anaerobe level legionella, mycoplasma, chlamydia is had to good action.Belong to the quick-acting antibacterial of trophophase.Under high concentration, there is bactericidal action, be one of medicine that the macrolide apoplexy due to endogenous wind is the strongest to the mycoplasma effect, be mainly used in preventing and treating pig, avian mycoplasmas disease, as the mycoplasma pneumonia of chronic respiratory disease of fowl (CRD) and infectiousness hole chamber inflammation and pig.
The antimicrobial spectrum of kanamycin sulfate is similar to streptomycin, but effect is slightly strong.Most of gram negative bacterias are had to powerful antibacterial action as escherichia coli, Bacillus proteus, Salmonella and pasteurella multocida etc., also more responsive to gold-coloured staphylococci and tubercule bacillus.Intramuscular injection is used for the various severe infections due to sensitive organism, as septicemia, urogenital infection, respiratory tract infection, Skin and soft tissue infection etc.
Trimethoprim is the broad-spectrum antiseptic synergist, can the antibacterial action of multiple antibiotics be increased substantially (but potentiation several times to tens times), and can reduce the appearance of drug resistance strain.
Injection means the sterile solution that the confession is injected in vivo, emulsion or the suspension that medicine is made, and for the sterilized powder concentrated solution of wiring solution-forming before use or suspension.The characteristics of injection, is mainly manifested in route of administration and organizes (liver) and directly inject tissue or blood vessel without digestive system and defence, so drug effect is rapid, is applicable to first aid.But also the curative effect of some injection is extended, to adapt to the needs in medical treatment.The dosage of injection is accurate, and reliable effect may suffer the impacts such as Digestive system, food, and make the dosage of taking that curative effect can not occur fully unlike endo-medicine.In addition, can make again some drugs performance positioning action.
Injectable sterile powder claims again the powder pin, and injection after dissolving with sterilized water for injection before use, be a kind of injection type more commonly used.Be applicable to unsettled medicine in water, particularly to wet heat sensitive antibiotic and biological product.
Summary of the invention
The purpose of this invention is to provide a kind of injection use compound potentiation tylosin tartrate for animals, it has quick, definite curative effect to poultry respiratory system infection and complication.
For achieving the above object, the technical solution adopted in the present invention is: a kind of injection use compound potentiation tylosin tartrate for animals, it is characterized in that, and by the component of following weight ratio, formed:
In described formula, amounts of components is strict, and except pain relief agents, other component does not almost have the leeway of adjusting.Only can on material choice, do following replacement:
Described cosolvent is citric acid or succinic acid or the two is composite.
Described pain relief agents is procaine hydrochloride or lidocaine hydrochloride or the two is composite.
The preparation method of injection of the present invention:
Take trimethoprim, the cosolvent of recipe quantity, mix by fluid energy mill and pulverize, cross 120 orders or thinner sieve;
With tylosin tartrate, kanamycin sulfate, pain relief agents, by the equivalent method of progressively increasing, mix homogeneously again;
Inspection of semifinished product content, dissolubility, qualified rear packing, packing, obtain.
Further, described pulverizing is to pulverize through fluid energy mill.
Further, described sieving as crossing 120 mesh sieves.
The usage of product of the present invention and consumption: first product of the present invention is dissolved as analog such as water for injection or ethylene glycol, ethanol with solvent for injection, then muscle or subcutaneous injection.In tylosin tartrate: amount once, every 1kg body weight, pig, fowl 5～13mg, once a day.
The injection use compound potentiation tylosin tartrate for animals of the present invention's development, include tylosin tartrate, kanamycin sulfate, three kinds of pharmaceutical compositions of trimethoprim.Three kinds of ingredients composite not only for indication more extensive, and enhancing evident in efficacy.And there is the following effect of having a mind to:
1, develop a kind of injection use compound potentiation tylosin tartrate for animals and preparation method thereof is provided for veterinary clinic;
2, solved due to the tylosin tartrate narrow antimicrobial spectrum, treatment can not fine control secondary infection during mycoplasma infection;
3, solve the problem that trimethoprim is insoluble in water, and paratartaric acid tylosin and kanamycin sulfate potentiation;
4, be injectable sterile powder, preparation stabilization, storage period is long;
5, rapid-action, duration of efficacy is long, and bioavailability is high;
6, use safety, determined curative effect, quality controllable;
7, dosage is accurate, easy to use;
8, irritating property is little, reduce to poultry stress.
The specific embodiment
Embodiment mono-
Tylosin tartrate 1g, kanamycin sulfate 1g, trimethoprim 0.2g, citric acid 0.2g, procaine hydrochloride 0.05g.
Preparation method:
Take respectively trimethoprim, the citric acid of recipe quantity, mix by fluid energy mill and pulverize, cross 120 mesh sieves, with tylosin tartrate, kanamycin sulfate, procaine hydrochloride, by the equivalent method of progressively increasing, mix homogeneously again, the inspection of semifinished product, packing, packing, product inspection, obtain.
Embodiment bis-
Tylosin tartrate 1g, kanamycin sulfate 1g, trimethoprim 0.2g, succinic acid 0.2g, procaine hydrochloride 0.05g.
Preparation method:
Take respectively trimethoprim, the succinic acid of recipe quantity, mix by fluid energy mill and pulverize, cross 120 mesh sieves, then mix homogeneously by the equivalent method of progressively increasing with tylosin tartrate, kanamycin sulfate, pain relief agents, the inspection of semifinished product, packing, packing, product inspection, warehouse-in, obtain.
Embodiment tri-
Tylosin tartrate 1g, kanamycin sulfate 1g, trimethoprim 0.2g, citric acid 0.2g, lidocaine hydrochloride 0.05g.
Preparation method:
Take respectively trimethoprim, the citric acid of recipe quantity, mix by fluid energy mill and pulverize, cross 150 mesh sieves, then mix homogeneously by the equivalent method of progressively increasing with tylosin tartrate, kanamycin sulfate, pain relief agents, the inspection of semifinished product, packing, packing, product inspection, warehouse-in, obtain.
Embodiment tetra-
Tylosin tartrate 1g, kanamycin sulfate 1g, trimethoprim 0.2g, succinic acid 0.2g, lidocaine hydrochloride 0.05g.
Preparation method:
Take respectively trimethoprim, the succinic acid of recipe quantity, mix by fluid energy mill and pulverize, cross 120 mesh sieves, then mix homogeneously by the equivalent method of progressively increasing with tylosin tartrate, kanamycin sulfate, pain relief agents, the inspection of semifinished product, packing, packing, product inspection, warehouse-in, obtain.
Embodiment five
Tylosin tartrate 0.5g, kanamycin sulfate 0.5g, trimethoprim 0.1g, citric acid 0.1g, procaine hydrochloride 0.05g.
Preparation method:
Take respectively trimethoprim, the citric acid of recipe quantity, mix by fluid energy mill and pulverize, cross 120 mesh sieves, then mix homogeneously by the equivalent method of progressively increasing with tylosin tartrate, kanamycin sulfate, pain relief agents, the inspection of semifinished product, packing, packing, product inspection, warehouse-in, obtain.
Embodiment six
Tylosin tartrate 0.5g, kanamycin sulfate 0.5g, trimethoprim 0.1g, succinic acid 0.1g, procaine hydrochloride 0.05g.
Preparation method:
Take respectively trimethoprim, the succinic acid of recipe quantity, mix by fluid energy mill and pulverize, sieve, then mix homogeneously by the equivalent method of progressively increasing with tylosin tartrate, kanamycin sulfate, pain relief agents, the inspection of semifinished product, packing, packing, product inspection, warehouse-in, obtain.
Embodiment seven
Tylosin tartrate 0.5g, kanamycin sulfate 0.5g, trimethoprim 0.1g, citric acid 0.1g, procaine hydrochloride 0.03g, lidocaine hydrochloride 0.02g.
Preparation method:
Take respectively trimethoprim, the cosolvent of recipe quantity, mix by fluid energy mill and pulverize, cross 120 mesh sieves, then mix homogeneously by the equivalent method of progressively increasing with tylosin tartrate, kanamycin sulfate, pain relief agents, the inspection of semifinished product, packing, packing, product inspection, warehouse-in, obtain.
Embodiment eight
Tylosin tartrate 0.5g, kanamycin sulfate 0.5g, trimethoprim 0.1g, citric acid 0.05g, succinic acid 0.05g, lidocaine hydrochloride 0.05g.
Preparation method:
Take respectively trimethoprim, the cosolvent of recipe quantity, mix by fluid energy mill and pulverize, sieve, then mix homogeneously by the equivalent method of progressively increasing with tylosin tartrate, kanamycin sulfate, pain relief agents, the inspection of semifinished product, packing, packing, product inspection, warehouse-in, obtain.
Result of study
1, prescription research
The present invention writes out a prescription with crude drug tylosin tartrate, kanamycin sulfate, trimethoprim, records one one of " Chinese veterinary pharmacopoeia " version in 2010." Chinese veterinary pharmacopoeia " record, similar to the erythromycin antimicrobial spectrum.A little less than effect to antibacterial, strong to the Mycoplasma effect, be one of medicine that the macrolide apoplexy due to endogenous wind is the strongest to the mycoplasma effect.Sensitive organism produces drug resistance to this product, and staphylococcus aureus has part crossing drug resistant phenomenon to this product and erythromycin; The antimicrobial spectrum of kanamycin sulfate is similar to streptomycin, but effect is slightly strong.Most of gram negative bacterias are had to powerful antibacterial action as escherichia coli, Bacillus proteus, Salmonella and pasteurella multocida etc., also more responsive to gold-coloured staphylococci and tubercule bacillus.Intramuscular injection is used for the various severe infections due to sensitive organism, as septicemia, urogenital infection, respiratory tract infection, Skin and soft tissue infection etc.; Trimethoprim is the broad-spectrum antiseptic synergist, can the antibacterial action of multiple antibiotics be increased substantially, and can reduce the appearance of drug resistance strain.
The present invention's prescription is by tylosin tartrate, kanamycin sulfate drug combination, through trimethoprim potentiation, clinical trial shows, in the effect and purposes basis of " Chinese veterinary pharmacopoeia " record, the pain produced in the time of solving the tylosin tartrate injection, control livestock and poultry respiratory and digestive tract disease effect are more remarkable, and reduce the generation of drug resistance.
2, stability study
Injection use compound potentiation tylosin tartrate product stability research for animals of the present invention, " veterinary drug stability test technical specification (trying) " way that system promulgates according to the Ministry of Agriculture, adopt temperature, humidity accelerated test and acceleration by light test, three batch samples are carried out to stability study.
2.1 temperature, humidity accelerated test
2.1.1 test material
Product of the present invention: injection use compound potentiation tylosin tartrate for animals
Batch number: 110701,110702,110703
Product requirement: commercially available back
2.1.2 experimental condition: adopt the medicine stability test case, temperature is adjusted to 40 ± 2 ℃, and relative humidity is controlled at 75 ± 5%.
2.1.3 observing time: product of the present invention is placed 6 months, and at duration of test, each month sampling secondary, detected product by stability high spot reviews project.
2.1.4 investigation project: character, content, the investigation project is determined according to " veterinary drug stability test technical specification (the trying) " way of promulgating for the Ministry of Agriculture.
2.1.5 test data
Name of product: injection use compound potentiation tylosin tartrate for animals, product batch number: 110701
Name of product: injection use compound potentiation tylosin tartrate for animals, product batch number: 110702
Name of product: injection use compound potentiation tylosin tartrate for animals, product batch number: 110703
2.2 acceleration by light test
2.2.1 test material
Product of the present invention: injection use compound potentiation tylosin tartrate for animals
Batch number: 110701,110702,110703
Product requirement: commercially available back
2.2.2 experimental condition: in test, with in the proof box of medicine strong illumination, illumination is 4500 native 500LX
2.2.3 observing time: get product of the present invention and pack in the water white transparency container, be positioned in the light durability proof box, place ten days under the condition of illumination 4500LX ± 500LX, sampling when walking in the 5th, ten days, detect by stability high spot reviews project.
2.2.4 investigation project: character, pH value, clarity, content, investigation project are determined according to " veterinary drug stability test technical specification (the trying) " way of promulgating for the Ministry of Agriculture.
2.2.5 test data
Name of product: injection use compound potentiation tylosin tartrate for animals, product batch number: 110701
Name of product: injection use compound potentiation tylosin tartrate for animals, product batch number: 110702
Name of product: injection use compound potentiation tylosin tartrate for animals, product batch number: 110703
2.3 result of study: product three batch samples of the present invention are investigated by temperature, humidity accelerated test and first accelerated test, it is all up to specification that result shows that product characteristics, pH value, clarity, content etc. detect within each investigation time, compares every detection index with the O month without significant degree.
3. the clinical trial of injection use compound potentiation tylosin tartrate for animals
Method: choose ill moving, be divided at random experimental group, matched group 1 and matched group 2:
(1) drug test group intramuscular injection injection use compound potentiation tylosin tartrate for animals of the present invention;
(2) medicine matched group 1 intramuscular injection injection tylosin tartrate matched group; Manufacturer: Chongqing gold nation animal pharmaceutical estate company limited, effective ingredient: tylosin tartrate, trimethoprim.
(3) medicine matched group 2 intramuscular injections kanamycin sulfate matched group; Manufacturer: the golden nation of gold celebrating animal pharmaceutical estate company limited, effective ingredient: kanamycin sulfate, trimethoprim.
Therapeutic dose: test group is in tylosin, 1kg body weight 5mg; Matched group 1 is in tylosin, 1kg body weight 10mg; Matched group 2 is in kanamycin sulfate, 1kg body weight 10mg.After treatment starts, with identical administering mode and corresponding disease, every day entry infected animal health situation of change, treat after 2 days and add up therapeutic outcome.
Result shows, matched group 1,2 comparisons of injection use compound potentiation tylosin tartrate for animals and folk prescription medicine, and the treatment disease effects obviously is better than matched group.The compound of the more existing tylosin tartrate of curative effect and trimethoprim or the compound of kanamycin sulfate and trimethoprim significantly strengthen.The disease of animal of take disappears fully as healing.
The clinical application effect statistics of injection use compound potentiation tylosin tartrate for animals
Claims (5)
1. an injection use compound potentiation tylosin tartrate for animals, is characterized in that, the component of following weight ratio, consists of:
2. a kind of injection use compound potentiation tylosin tartrate for animals according to claim 1 is characterized in that: described cosolvent is citric acid or succinic acid or the two is composite.
3. a kind of injection use compound potentiation tylosin tartrate for animals according to claim 1 and 2 is characterized in that: described pain relief agents is procaine hydrochloride or lidocaine hydrochloride or the two is composite.
4. a kind of injection use compound potentiation tylosin tartrate for animals according to claim 1, is characterized in that: 0.1 part of described pain relief agents.
5. a kind of injection use compound potentiation tylosin tartrate for animals according to claim 1, is characterized in that: 1 part of described tylosin tartrate, 1 part of kanamycin sulfate, 0.2 part of trimethoprim, 0.1 part of citric acid, 0.1 part of succinic acid, 0.1 part of lidocaine hydrochloride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310364033.XA CN103432150B (en) | 2012-08-06 | 2012-08-06 | The compound medicine of potentiation tylosin tartrate soluble powder |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310364033.XA CN103432150B (en) | 2012-08-06 | 2012-08-06 | The compound medicine of potentiation tylosin tartrate soluble powder |
| CN 201210277167 CN102784159B (en) | 2012-08-06 | 2012-08-06 | Compound synergistic tartaric acid tylosin for injection of livestock |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210277167 Division CN102784159B (en) | 2012-08-06 | 2012-08-06 | Compound synergistic tartaric acid tylosin for injection of livestock |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103432150A true CN103432150A (en) | 2013-12-11 |
| CN103432150B CN103432150B (en) | 2015-12-09 |
Family
ID=47149880
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310364033.XA Expired - Fee Related CN103432150B (en) | 2012-08-06 | 2012-08-06 | The compound medicine of potentiation tylosin tartrate soluble powder |
| CN 201210277167 Expired - Fee Related CN102784159B (en) | 2012-08-06 | 2012-08-06 | Compound synergistic tartaric acid tylosin for injection of livestock |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210277167 Expired - Fee Related CN102784159B (en) | 2012-08-06 | 2012-08-06 | Compound synergistic tartaric acid tylosin for injection of livestock |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN103432150B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104892705A (en) * | 2015-05-11 | 2015-09-09 | 成都中牧生物药业有限公司 | Preparation technology of tylosin tartrate for injection |
| CN104926899A (en) * | 2015-05-11 | 2015-09-23 | 成都中牧生物药业有限公司 | Preparation process avoiding the reduction of tylosin tartrate original drug potency |
| CN115068420A (en) * | 2022-07-27 | 2022-09-20 | 石家庄石牧药业有限公司 | Tylosin tartrate solution for livestock and poultry and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107308176A (en) * | 2017-07-05 | 2017-11-03 | 山东中牧兽药有限公司 | A kind of injection Tylosin Tartrate and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1843329A (en) * | 2006-05-17 | 2006-10-11 | 天津生机集团有限公司 | Compound amikacin sulfate injection for animal and its preparation method |
| CN101468032A (en) * | 2007-12-26 | 2009-07-01 | 天津瑞普生物技术集团有限公司 | Soluble powder for treating respiratory illness of livestock and poultry |
| CN101822688A (en) * | 2010-05-19 | 2010-09-08 | 陈建波 | Compound tylosin injection for animals and preparation method thereof |
-
2012
- 2012-08-06 CN CN201310364033.XA patent/CN103432150B/en not_active Expired - Fee Related
- 2012-08-06 CN CN 201210277167 patent/CN102784159B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1843329A (en) * | 2006-05-17 | 2006-10-11 | 天津生机集团有限公司 | Compound amikacin sulfate injection for animal and its preparation method |
| CN101468032A (en) * | 2007-12-26 | 2009-07-01 | 天津瑞普生物技术集团有限公司 | Soluble powder for treating respiratory illness of livestock and poultry |
| CN101822688A (en) * | 2010-05-19 | 2010-09-08 | 陈建波 | Compound tylosin injection for animals and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 倪谷音: "兽医常用抗微生物药物的合理使用", 《动保药品》, no. 204, 31 August 2006 (2006-08-31), pages 50 - 51 * |
| 吕惠序: "养猪场如何合理应用抗菌药物", 《养猪》, no. 1, 31 December 2010 (2010-12-31), pages 59 - 64 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104892705A (en) * | 2015-05-11 | 2015-09-09 | 成都中牧生物药业有限公司 | Preparation technology of tylosin tartrate for injection |
| CN104926899A (en) * | 2015-05-11 | 2015-09-23 | 成都中牧生物药业有限公司 | Preparation process avoiding the reduction of tylosin tartrate original drug potency |
| CN115068420A (en) * | 2022-07-27 | 2022-09-20 | 石家庄石牧药业有限公司 | Tylosin tartrate solution for livestock and poultry and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102784159B (en) | 2013-08-21 |
| CN103432150B (en) | 2015-12-09 |
| CN102784159A (en) | 2012-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101953841B (en) | Swine eperythrozoonosis-resisting compound long-acting oxytetracycline injection and preparation method thereof | |
| CN102784159B (en) | Compound synergistic tartaric acid tylosin for injection of livestock | |
| CN101972226B (en) | Veterinary doxycycline hydrochloride injection and preparation method thereof | |
| CN100586441C (en) | Compound sulfamonomethoxine sodium injection and preparation method thereof | |
| CN103143019A (en) | Compound preparation for treating porcine contagious pleuropneumonia and respiratory tract mixed infection and preparation method thereof | |
| CN105943629A (en) | Traditional Chinese medicine compound preparation for treating piglet diarrhea and preparation method thereof | |
| CN103405463A (en) | Preparation method of synergistic tylosin tartrate soluble powder compound medicine | |
| CN103405465A (en) | Preparation method of medicine for treating respiratory system infection of livestock and poultry | |
| CN102784158B (en) | Preparation method of compound synergy tylosin tartrate for veterinary injection | |
| CN103721240B (en) | Compound formulation for treating bacterial infection of digestive tract of livestock and poultry and preparation method of compound formulation | |
| CN103405466B (en) | Compound synergistic tylosin tartrate | |
| CN106620668A (en) | Compound tilmicosin solid dispersing agent and preparation method thereof | |
| CN102813909B (en) | Compound doxycycline hydrochloride composition for preventing and treating colibacillosis and chronic respiratory disease of poultry as well as preparation method thereof | |
| CN102755337B (en) | Compound florfenicol injection and preparation method thereof | |
| CN102861100A (en) | Compound injection for treating animal respiratory tracts and preparation method thereof | |
| CN100548306C (en) | A kind of injection and preparation technology thereof who treats eperythrozoonosis of domestic animal | |
| CN103405464B (en) | Medicine for treating respiratory system infection of livestock and poultry | |
| CN103432151A (en) | Preparation method for compound synergistic tylosin tartrate | |
| CN110151779A (en) | A kind of composition that treating batrachia torticollis disease and its application | |
| CN103622976B (en) | Long-acting veterinary compound doxycycline hydrochloride injection and preparation method thereof | |
| RU2574025C2 (en) | Agent for treatment of acute gastrointestinal diseases of newborn lambs | |
| CN106361704B (en) | A kind of injection ceftiofur sodium medicament slow release colloid powder-injection and preparation method thereof | |
| CN105456281B (en) | A kind of veterinary medical composition and its production and use | |
| CN104758391B (en) | Stop dysentery compound Chinese medicinal preparation and its production method for animals | |
| RU2295332C2 (en) | Preparation for treatment of bacterial and/or protozoa infection in animals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151209 Termination date: 20160806 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |